Patents Assigned to Pfizer Inc.
  • Publication number: 20210163455
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Patent number: 11020469
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 1, 2021
    Assignee: Pfizer Inc.
    Inventors: Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
  • Patent number: 11021528
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Pfizer Inc., Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 11020376
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: June 1, 2021
    Assignee: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa Jane Birch, Stephen Mark McAllister, Martin Gregory Rowland, Ian Leonard Smales
  • Patent number: 11014911
    Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: May 25, 2021
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
  • Patent number: 11014909
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: May 25, 2021
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Patent number: 11014908
    Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 25, 2021
    Assignee: Pfizer Inc.
    Inventors: Ariamala Gopalsamy, Arjun Venkat Narayanan, Agustin Casimiro-Garcia, Chulho Choi, David Hepworth, David Walter Piotrowski, Hatice Gizem Yayla, Jayasankar Jasti, Lee Richard Roberts, Lyn Howard Jones, Mihir Dineshkumar Parikh, Ming Zhu Chen, Olugbeminiyi Omezia Fadeyi, Ralph Pelton Robinson, Jr., Robert Lee Dow, Shawn Cabral
  • Publication number: 20210145957
    Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 20, 2021
    Applicant: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G.K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
  • Publication number: 20210128729
    Abstract: The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-vascular endothelial growth factor (VEGF) antibody.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 6, 2021
    Applicant: PFIZER INC.
    Inventors: REBECCA LEE INGRAM, SARAH ELIZABETH WEISER
  • Publication number: 20210121555
    Abstract: The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 29, 2021
    Applicant: Pfizer Inc.
    Inventors: Mingming Han, Avvari Krishna Prasad, David Cooper, Wendy Jo Watson
  • Patent number: 10988463
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: April 27, 2021
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Publication number: 20210115413
    Abstract: Disclosed herein are methods of generating proteoglycans with distinct glycan structures in engineered, non-naturally occurring eukaryotic cells. These methods make accessible a dynamic range of protein glycosylation. Compositions of engineered, non-naturally occurring cells capable of generating these proteoglycans are also disclosed herein.
    Type: Application
    Filed: June 20, 2019
    Publication date: April 22, 2021
    Applicants: Massachusetts Institute of Technology, Pfizer Inc.
    Inventors: Michelle Chang, Leonid A. Gaydukov, Giyoung Jung, Nevin M. Summers, Timothy Kuan-Ta Lu, Ron Weiss, John Scarcelli, Richard Cornell, Jeffrey Marshall, Bruno Figueroa, Wen Allen Tseng
  • Publication number: 20210115159
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Application
    Filed: November 18, 2020
    Publication date: April 22, 2021
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
  • Patent number: 10982198
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
    Type: Grant
    Filed: August 19, 2018
    Date of Patent: April 20, 2021
    Assignee: Pfizer Inc.
    Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
  • Patent number: 10980815
    Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: April 20, 2021
    Assignee: Pfizer Inc.
    Inventors: Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
  • Patent number: 10975065
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: April 13, 2021
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
  • Publication number: 20210100796
    Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Applicant: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • Publication number: 20210100798
    Abstract: Described herein are compounds of Formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 8, 2021
    Applicant: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • Patent number: 10967068
    Abstract: The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 6, 2021
    Assignees: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Russell George Dushin, Pavel Strop, Magdalena Grazyna Dorywalska, Ludivine Moine
  • Patent number: 10968242
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: April 6, 2021
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala